Cargando…

The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Panzuto, Francesco, Ricci, Claudio, Rinzivillo, Maria, Magi, Ludovica, Marasco, Matteo, Lamberti, Giuseppe, Casadei, Riccardo, Campana, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605244/
https://www.ncbi.nlm.nih.gov/pubmed/36294448
http://dx.doi.org/10.3390/jcm11206127
_version_ 1784818018012889088
author Panzuto, Francesco
Ricci, Claudio
Rinzivillo, Maria
Magi, Ludovica
Marasco, Matteo
Lamberti, Giuseppe
Casadei, Riccardo
Campana, Davide
author_facet Panzuto, Francesco
Ricci, Claudio
Rinzivillo, Maria
Magi, Ludovica
Marasco, Matteo
Lamberti, Giuseppe
Casadei, Riccardo
Campana, Davide
author_sort Panzuto, Francesco
collection PubMed
description Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measured as incidence density ratio (IDR) at one year. The secondary endpoints were the disease control rate (DCR) and severe adverse events (SAEs). The heterogeneity (I2), when high (>50%), was interpreted by performing a univariate metaregression analysis, analyzing as covariates: type and design of the study, location (Europe or USA), sample size, grading according to 2017 WHO, the metastatic disease rate, previous therapy including surgery, and quality of the study. Results: A total of 11 studies with 783 patients were included. The IDR was 62 new progressions of 100 patients treated with HD-SSA every one year. The heterogeneity was high. The study’s year, type and design, primary tumor, grading, previous treatments, and quality of the studies did not influence the IDR. The IDR was significantly higher in USA centers and studies with more than 50 patients. The IDR was lower when a high rate of metastatic patients was present in the studies. The DCR was 45%. The heterogeneity was high. The DCR was lower in USA studies and in prospective trials. Conclusion: Given the limited efficacy of HD-SSA in preventing the disease progression in unresectable GEP-NENs after failure of standard dose SSA, the use of this therapeutic approach is advisable in selected cases when other antiproliferative treatments are not feasible.
format Online
Article
Text
id pubmed-9605244
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96052442022-10-27 The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis Panzuto, Francesco Ricci, Claudio Rinzivillo, Maria Magi, Ludovica Marasco, Matteo Lamberti, Giuseppe Casadei, Riccardo Campana, Davide J Clin Med Article Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measured as incidence density ratio (IDR) at one year. The secondary endpoints were the disease control rate (DCR) and severe adverse events (SAEs). The heterogeneity (I2), when high (>50%), was interpreted by performing a univariate metaregression analysis, analyzing as covariates: type and design of the study, location (Europe or USA), sample size, grading according to 2017 WHO, the metastatic disease rate, previous therapy including surgery, and quality of the study. Results: A total of 11 studies with 783 patients were included. The IDR was 62 new progressions of 100 patients treated with HD-SSA every one year. The heterogeneity was high. The study’s year, type and design, primary tumor, grading, previous treatments, and quality of the studies did not influence the IDR. The IDR was significantly higher in USA centers and studies with more than 50 patients. The IDR was lower when a high rate of metastatic patients was present in the studies. The DCR was 45%. The heterogeneity was high. The DCR was lower in USA studies and in prospective trials. Conclusion: Given the limited efficacy of HD-SSA in preventing the disease progression in unresectable GEP-NENs after failure of standard dose SSA, the use of this therapeutic approach is advisable in selected cases when other antiproliferative treatments are not feasible. MDPI 2022-10-18 /pmc/articles/PMC9605244/ /pubmed/36294448 http://dx.doi.org/10.3390/jcm11206127 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Panzuto, Francesco
Ricci, Claudio
Rinzivillo, Maria
Magi, Ludovica
Marasco, Matteo
Lamberti, Giuseppe
Casadei, Riccardo
Campana, Davide
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title_full The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title_fullStr The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title_full_unstemmed The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title_short The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
title_sort antiproliferative activity of high-dose somatostatin analogs in gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605244/
https://www.ncbi.nlm.nih.gov/pubmed/36294448
http://dx.doi.org/10.3390/jcm11206127
work_keys_str_mv AT panzutofrancesco theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT ricciclaudio theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT rinzivillomaria theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT magiludovica theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT marascomatteo theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT lambertigiuseppe theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT casadeiriccardo theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT campanadavide theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT panzutofrancesco antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT ricciclaudio antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT rinzivillomaria antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT magiludovica antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT marascomatteo antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT lambertigiuseppe antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT casadeiriccardo antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis
AT campanadavide antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis